N
EIGR

Nuveen’s Eiger BioPharmaceuticals, Inc. EIGR Stock Holding History

Nuveen’s Portfolio EIGR Stock Details EIGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-3,403
Closed -$768K – 3282
2022
Q3 		$768K Buy
3,403
+77
+2% +$18.9K ﹤0.01% 2849
2022
Q2 		$629K Sell
3,326
-493
-13% -$99.4K ﹤0.01% 2957
2022
Q1 		$990K Sell
3,819
-151
-4% -$23.9K ﹤0.01% 2822
2021
Q4 		$631K Sell
3,970
-428
-10% -$82.8K ﹤0.01% 3007
2021
Q3 		$952K Buy
4,398
+73
+2% +$17.4K ﹤0.01% 3003
2021
Q2 		$1.1M Buy
4,325
+594
+16% +$148K ﹤0.01% 2973
2021
Q1 		$991K Sell
3,731
-133
-3% -$41.9K ﹤0.01% 2887
2020
Q4 		$1.42M Buy
3,864
+655
+20% +$188K ﹤0.01% 2671
2020
Q3 		$783K Buy
3,209
+14
+0.4% +$4.36K ﹤0.01% 2793
2020
Q2 		$920K Sell
3,195
-4,627
-59% -$1.36M ﹤0.01% 2650
2020
Q1 		$1.6M Buy
7,822
+5,188
+197% +$1.65M ﹤0.01% 2296
2019
Q4 		$1.18M Buy
2,634
+645
+32% +$229K ﹤0.01% 2628
2019
Q3 		$611K Sell
1,989
-1,247
-39% -$405K ﹤0.01% 2882
2019
Q2 		$1.03M Buy
+3,236
New +$1.12M ﹤0.01% 2728

Other funds holding EIGR

Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Nuveen's EIGR Position: Q4 2022 in Review

Nuveen sold out of Eiger BioPharmaceuticals, Inc. (EIGR) in Q4 2022, closing a stake of 3,403 shares — an estimated $768K sold.

Nuveen first reported a position in EIGR in Q2 2019 and held it in 14 quarters. The position peaked at $1.6M in Q1 2020. 81 funds tracked by Wall St. Rank hold EIGR as of Q4 2022.

  • Nuveen reported no remaining Eiger BioPharmaceuticals, Inc. position as of Q4 2022 after selling out during the quarter.
  • Nuveen sold 3,403 Eiger BioPharmaceuticals, Inc. shares in Q4 2022, an estimated $768K.
  • Nuveen first reported a position in Eiger BioPharmaceuticals, Inc. in Q2 2019 and held it in 14 quarters.
  • Nuveen's Eiger BioPharmaceuticals, Inc. position peaked at $1.6M in Q1 2020.
  • 81 funds tracked by Wall St. Rank held Eiger BioPharmaceuticals, Inc. as of Q4 2022.

Based on Nuveen's 13F filing for Q4 2022, filed 14 Feb 2023.